SynAct PharmaSynAct Pharma CEO has acquired shares in the company
SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through a novel therapeutic approach known as “pro-resolution”, today announced that its CEO, Jeppe Øvlesen, has acquired 20,313 shares in the company.
“SynAct has an exciting future ahead, and I am very confident in the potential we are building. My investment reflects my strong belief in the company’s potential and my long-term commitment to SynAct,” said CEO Jeppe Øvlesen.
The shares were acquired on Nasdaq Stockholm.
Bilagor & Media
0 kommentarer
Kommentera nyheten
När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!
Logga in eller skapa ett gratis konto för att kommentera nyheten!
